|
|
 | | | |
- close
- close
- close
- close
Eli Lilly and Company (LLY) |
QUOTE AND NEWS
PR Newswire
May 23
Comment
PHILADELPHIA, May 23, 2012 /PRNewswire/ -- Today, the American College of Endocrinology (ACE) and Lilly Diabetes launched the "EmPower Diabetes Emergency Plan" - a newly designed resource to help people with diabetes prepare for emergency situations
FierceBiotech
May 22
Comment
The FDA's demanding requirements on cardio safety data has made diabetes one of the most challenging diseases in the drug development world. Today, Eli Lilly ($LLY) demonstrated that its late-stage diabetes drug dulaglutide cleared an important...
PR Newswire
May 22
Comment
NEW YORK, May 22, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that dulaglutide, its investigational, long-acting glucagon-like peptide 1 (GLP-1) analog being studied as a once-weekly treatment for type 2 diabetes, met its
MedPage Today
May 16
Comment
CHICAGO (MedPage Today) -- A well-known anti-psychotic drug can help cancer patients bear some of the side effects of chemotherapy, a researcher said.
Market Intelligence Center
May 16
Comment
Eli Lilly (NYSE:LLY) closed Tuesday's wandering trading session at $40.58. In the past year, the stock has hit a 52-week low of $33.75 and 52-week high of $42.03. Eli Lilly (LLY) stock has been showing support around $40.18 and resistance in the...
PR Newswire
May 14
Comment
INDIANAPOLIS, May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from more than 25 studies at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1 - 5, 2012, including
PR Newswire
May 14
Comment
INDIANAPOLIS, May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from several molecules that make up its clinical oncology pipeline during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) held
FiercePharma
May 10
Comment
Don't count pharma out in the sales-rep overtime fight. As Pharmalot reports, a U.S. appeals court has denied overtime for Eli Lilly ($LLY) and Abbott Laboratories ($ABT) sales reps. The reps qualify for the Fair Labor Standards Act's...
Market Intelligence Center
May 10
Comment
Eli Lilly (NYSE:LLY) closed Wednesday's downbeat trading session at $41.30. In the past year, the stock has hit a 52-week low of $33.75 and 52-week high of $42.03. Eli Lilly (LLY) stock has been showing support around $40.79 and resistance in the...
FierceBiotech
May 7
Comment
A secretive startup at Lilly Ventures in Indianapolis has grabbed $4.6 million of a documented $15 million round of equity financing, MedCity News reported, citing SEC documents. The recently founded Esanex doesn't appear to have a website or a...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
| |||||||
